Wave life sciences announces proposed public offering of ordinary shares and pre-funded warrants

Cambridge, mass., sept. 24, 2024 (globe newswire) -- wave life sciences ltd. (nasdaq: wve), a clinical-stage biotechnology company focused on unlocking the broad potential of rna medicines to transform human health, announced today that it has commenced an underwritten public offering of $175 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. in connection with the offering, wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. all of the securities in the offering will be sold by wave life sciences.
WVE Ratings Summary
WVE Quant Ranking